Filing Flows › Arvinas (ARVN) › Recalls, complaints & regulation
Arvinas (ARVN): clinical trials
Arvinas (ARVN) beyond its filings: 3 active clinical trials.
Arvinas' latest quarter
Arvinas, Q3 2026: revenue $500K (-99% year over year), net loss $53.9M, operating cash flow −$10.4M. The chart follows the revenue to costs, profit and cash.
Questions
How many clinical trials does Arvinas have?
3 active studies on ClinicalTrials.gov, 0 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.